Comprehensive suppression of the renin–angiotensin–aldosterone system in chronic kidney disease: Covering all of the bases

Department of Medicine, Indiana University Medical Center, Indianapolis, Indiana 46202, USA.
Kidney International (Impact Factor: 8.56). 01/2007; 70(12):2051-3. DOI: 10.1038/
Source: PubMed


Reducing proteinuria and blood pressure in chronic kidney disease (CKD) decreases rate of progression. Inhibition of the renin-angiotensin system by angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers is beneficial in reducing proteinuria but incomplete in suppressing aldosterone production and its renal effects. Adding aldosterone receptor blockers to these other agents may further halt the progression of CKD.

Download full-text


Available from: Myron H Weinberger, Aug 14, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Chronic kidney disease (CKD) occurs in all age groups, including children. Regardless of the underlying cause, CKD is characterized by progressive scarring that ultimately affects all structures of the kidney. The relentless progression of CKD is postulated to result from a self-perpetuating vicious cycle of fibrosis activated after initial injury. We will review possible mechanisms of progressive renal damage, including systemic and glomerular hypertension, various cytokines and growth factors, with special emphasis on the renin-angiotensin-aldosterone system (RAAS), podocyte loss, dyslipidemia and proteinuria. We will also discuss possible specific mechanisms of tubulointerstitial fibrosis that are not dependent on glomerulosclerosis, and possible underlying predispositions for CKD, such as genetic factors and low nephron number.
    Pediatric Nephrology 01/2008; 22(12):2011-22. DOI:10.1007/s00467-007-0524-0 · 2.86 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study evaluated the effect of spironolactone in the renal function alterations induced by cyclosporine A (CsA) in rats. Male Wistar rats fed with an unrestricted sodium diet received CsA 15 mg/kg/day or CsA at the same dosage plus 20 mg/kg/day of spironolactone. Another group received only saline. The animals that had proteinuria > 50 mg/24h or serum creatinine > 1.0 mg% were excluded, and after five weeks, the remaining rats were analyzed again for these parameters. At the end of the fifth week, these animals were also sacrificed, and their kidneys were analyzed histologically. The animals that received CsA isolated or in association with spironolactone presented increase in serum creatinine. However, the comparison of the relative variation [Delta% = ([final - initial] / initial) x 100] of the serum creatinine concentrations in the beginning and at the end of the experiment among the animal groups showed a significant increase in the CsA group compared with the saline group (44.17 +/- 30.7% vs. -6.19 +/- 14.5%; p = 0.005), whereas there was no difference between the CsA + spironolactone and the saline group. In all of the animal groups, the values of 24-hour proteinuria were similar at the end of the experiment, and no renal histological alterations were observed. This experimental model of nephrotoxicity by CsA in rats without salt restriction in the diet showed that CsA reduced the glomerular filtration and suggested that the blockage of aldosterone receptors prevented, at least partially, the reduction in renal function induced by CsA.
    Renal Failure 02/2008; 30(4):439-42. DOI:10.1080/08860220801947397 · 0.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this review is to look at the role of aldosterone in the progression of chronic kidney disease. The reduction of blood pressure and proteinuria in patients suffering from chronic kidney disease decreases the rate of disease progression. Suppression of angiotensin formation by angiotensin converting enzyme inhibitors and blockade of the angiotensin II receptor by angiotensin II type 1 antagonists are powerful therapeutic strategies that effectively lower blood pressure and slow the progression of renal disease. These therapies, however, provide only imperfect protection, since they cannot always prevent endstage renal failure. Aldosterone plays a significant role in the pathogenesis of arterial hypertension and renal disease. Angiotensin converting enzyme inhibitors and angiotensin II type 1 antagonists are incomplete in suppressing aldosterone production and 'aldosterone breakthrough' can be observed under continued treatment. Aldosterone blockade reduces blood pressure in virtually all patients with hypertension. In proteinuric patients, the addition of an aldosterone antagonist to an angiotensin converting enzyme inhibitor or to angiotensin II type 1 antagonists reduces proteinuria. The use of aldosterone antagonists in addition to either angiotensin converting enzyme inhibitors or angiotensin II type 1 antagonists in proteinuric patients reduces proteinuria, which may translate into preservation of the glomerular filtration rate in the longer term. Therefore, blockade of the aldosterone pathway may prove to be a beneficial therapy for chronic kidney disease.
    Current Opinion in Nephrology and Hypertension 02/2008; 17(1):44-50. DOI:10.1097/MNH.0b013e3282f29028 · 3.86 Impact Factor
Show more